哮喘中的2型炎症——多数存在，许多不存在。
Type 2 inflammation in asthma--present in most, absent in many.
作者信息
Fahy John V
机构信息
Division of Pulmonary and Critical Care Medicine and the Cardiovascular Research Institute, Room 1307, Health Sciences East, 513 Parnassus Avenue, San Francisco, California 94143, USA.
出版信息
Nat Rev Immunol. 2015 Jan;15(1):57-65. doi: 10.1038/nri3786.
Abstract
Asthma is one of the most common chronic immunological diseases in humans, affecting people from childhood to old age. Progress in treating asthma has been relatively slow and treatment guidelines have mostly recommended empirical approaches on the basis of clinical measures of disease severity rather than on the basis of the underlying mechanisms of pathogenesis. An important molecular mechanism of asthma is type 2 inflammation, which occurs in many but not all patients. In this Opinion article, I explore the role of type 2 inflammation in asthma, including lessons learnt from clinical trials of inhibitors of type 2 inflammation. I consider how dichotomizing asthma according to levels of type 2 inflammation--into 'T helper 2 (TH2)-high' and 'TH2-low' subtypes (endotypes)--has shaped our thinking about the pathobiology of asthma and has generated new interest in understanding the mechanisms of disease that are independent of type 2 inflammation.
摘要
哮喘是人类最常见的慢性免疫疾病之一，影响着从儿童到老年的人群。哮喘治疗进展相对缓慢，治疗指南大多基于疾病严重程度的临床指标推荐经验性方法，而非基于发病机制的潜在机制。哮喘的一个重要分子机制是2型炎症，许多但并非所有患者都会出现这种炎症。在这篇观点文章中，我探讨了2型炎症在哮喘中的作用，包括从2型炎症抑制剂临床试验中吸取的经验教训。我思考了根据2型炎症水平将哮喘分为“2型辅助性T细胞（TH2）高”和“TH2低”亚型（内型）如何塑造了我们对哮喘病理生物学的认识，并引发了对理解独立于2型炎症的疾病机制的新兴趣。
相似文献
1
Type 2 inflammation in asthma--present in most, absent in many.哮喘中的2型炎症——多数存在，许多不存在。
Nat Rev Immunol. 2015 Jan;15(1):57-65. doi: 10.1038/nri3786.
2
Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.重新审视哮喘中的2型高气道炎症和2型低气道炎症：当前认知与治疗意义
Clin Exp Allergy. 2017 Feb;47(2):161-175. doi: 10.1111/cea.12880.
3
Characterization of asthma endotypes: implications for therapy.哮喘内型的特征：对治疗的意义。
Ann Allergy Asthma Immunol. 2016 Aug;117(2):121-5. doi: 10.1016/j.anai.2016.05.016.
4
Development of eosinophilic inflammation is independent of B-T cell interaction in a chronic house dust mite-driven asthma model.在慢性屋尘螨诱发的哮喘模型中，嗜酸性粒细胞炎症的发展独立于B细胞与T细胞的相互作用。
Clin Exp Allergy. 2017 Apr;47(4):551-564. doi: 10.1111/cea.12834. Epub 2016 Nov 22.
5
STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model.STAT3 抑制可预防哮喘小鼠模型中的肺部炎症、重塑以及 Th2 和 Th17 细胞的积累。
Allergy. 2016 Dec;71(12):1684-1692. doi: 10.1111/all.12937. Epub 2016 Jun 23.
6
Interleukin-10: The missing link in asthma regulation?白细胞介素-10：哮喘调节中缺失的环节？
Am J Respir Cell Mol Biol. 1999 Nov;21(5):562-3. doi: 10.1165/ajrcmb.21.5.f171.
7
Dectin-2 promotes house dust mite-induced T helper type 2 and type 17 cell differentiation and allergic airway inflammation in mice.Dectin-2 促进屋尘螨诱导的 T 辅助细胞 2 型和 17 型分化以及小鼠过敏性气道炎症。
Am J Respir Cell Mol Biol. 2014 Aug;51(2):201-9. doi: 10.1165/rcmb.2013-0522OC.
8
Current Understanding of Asthma Pathogenesis and Biomarkers.当前对哮喘发病机制和生物标志物的认识。
Cells. 2022 Sep 5;11(17):2764. doi: 10.3390/cells11172764.
9
Asthma Was Talking, But We Weren't Listening. Missed or Ignored Signals That Have Slowed Treatment Progress.哮喘在诉说，而我们却充耳不闻。那些被错过或忽视的信号减缓了治疗进程。
Ann Am Thorac Soc. 2016 Mar;13 Suppl 1(Suppl 1):S78-82. doi: 10.1513/AnnalsATS.201508-515MG.
10
Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Rα-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice.四氢姜黄素是姜黄素的主要代谢产物，可通过减轻 Th2 反应和抑制哮喘小鼠的 IL-4Rα-Jak1-STAT6 和 Jagged1/Jagged2-Notch1/Notch2 通路来改善过敏性气道炎症。
Clin Exp Allergy. 2018 Nov;48(11):1494-1508. doi: 10.1111/cea.13258. Epub 2018 Sep 12.
引用本文的文献
1
Predictive Factors and Clinical Markers of Recurrent Wheezing and Asthma After RSV Infection.呼吸道合胞病毒感染后反复喘息和哮喘的预测因素及临床标志物
Viruses. 2025 Jul 31;17(8):1073. doi: 10.3390/v17081073.
2
Investigating the Underlying Mechanisms of Ma-Xing-Shi-Gan-Tang on Asthma via Metabolomics and Network Pharmacology.基于代谢组学和网络药理学探究麻杏石甘汤治疗哮喘的潜在机制
J Inflamm Res. 2025 Aug 18;18:11245-11262. doi: 10.2147/JIR.S515631. eCollection 2025.
3
AAV-mediated MUC5AC siRNA delivery to prevent mucociliary dysfunction in asthma.腺相关病毒介导的MUC5AC小干扰RNA递送用于预防哮喘中的黏液纤毛功能障碍。
Gene Ther. 2025 Aug 23. doi: 10.1038/s41434-025-00564-3.
4
Obesity indicators and female asthma risk: the mediating role of white blood cell count based on NHANES data analysis.肥胖指标与女性哮喘风险：基于美国国家健康与营养检查调查（NHANES）数据分析的白细胞计数的中介作用
BMC Pulm Med. 2025 Aug 21;25(1):399. doi: 10.1186/s12890-025-03885-6.
5
Quality of Life in Patients With Type 2 Inflammatory Asthma.2型炎症性哮喘患者的生活质量
Open Respir Arch. 2025 Jul 1;7(4):100461. doi: 10.1016/j.opresp.2025.100461. eCollection 2025 Oct-Dec.
6
BACH2 drives the development and function of group 2 innate lymphoid cells.BACH2驱动2型固有淋巴细胞的发育和功能。
Sci Adv. 2025 Aug;11(31):eads4323. doi: 10.1126/sciadv.ads4323. Epub 2025 Aug 1.
7
Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.重度哮喘的靶向生物疗法：作用机制、生物标志物及临床应用
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1021. doi: 10.3390/ph18071021.
8
The immunology of asthma.哮喘的免疫学
Nat Immunol. 2025 Aug;26(8):1233-1245. doi: 10.1038/s41590-025-02212-9. Epub 2025 Jul 29.
9
Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.与安慰剂加持续高剂量吸入性糖皮质激素（ICS）相比，度普利尤单抗加中等剂量ICS可改善未得到控制的中度至重度2型哮喘儿童的治疗效果。
Pediatr Pulmonol. 2025 Jul;60(7):e71197. doi: 10.1002/ppul.71197.
10
The Role of Alarmins in the Pathogenesis of Asthma.警报素在哮喘发病机制中的作用。
Biomolecules. 2025 Jul 11;15(7):996. doi: 10.3390/biom15070996.
本文引用的文献
1
Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation.鼻病毒诱导的白细胞介素-25在哮喘加重期驱动2型免疫反应和过敏性肺部炎症。
Sci Transl Med. 2014 Oct 1;6(256):256ra134. doi: 10.1126/scitranslmed.3009124.
2
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.美泊利珠单抗在嗜酸性粒细胞性哮喘中的口服糖皮质激素节省作用。
N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.
3
Mepolizumab treatment in patients with severe eosinophilic asthma.美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘患者。
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.
4
Epigenetic regulation of asthma and allergic disease.哮喘与过敏性疾病的表观遗传调控
Allergy Asthma Clin Immunol. 2014 May 28;10(1):27. doi: 10.1186/1710-1492-10-27. eCollection 2014.
5
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.抗 TSLP 抗体对变应原诱导的哮喘反应的影响。
N Engl J Med. 2014 May 29;370(22):2102-10. doi: 10.1056/NEJMoa1402895. Epub 2014 May 20.
6
Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.奥马珠单抗治疗控制不佳的过敏性鼻炎：随机临床试验的系统评价和荟萃分析。
J Allergy Clin Immunol Pract. 2014 May-Jun;2(3):332-40.e1. doi: 10.1016/j.jaip.2014.02.001.
7
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.奥马珠单抗治疗或不治疗中重度哮喘患者的恶性肿瘤发病率。
J Allergy Clin Immunol. 2014 Sep;134(3):560-567.e4. doi: 10.1016/j.jaci.2014.02.007. Epub 2014 Mar 27.
8
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.抗 IL-13mAb 在重症哮喘患者中的疗效和安全性：一项随机试验。
J Allergy Clin Immunol. 2014 Apr;133(4):989-96. doi: 10.1016/j.jaci.2014.01.002. Epub 2014 Feb 28.
9
Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents.评估城市内儿童和青少年奥马珠单抗的剂量策略和药效学。
J Allergy Clin Immunol Pract. 2013 Mar;1(2):163-71. doi: 10.1016/j.jaip.2013.01.011. Epub 2013 Feb 26.
10
The relationships between environmental bacterial exposure, airway bacterial colonization, and asthma.环境细菌暴露、气道细菌定植与哮喘之间的关系。
Curr Opin Allergy Clin Immunol. 2014 Apr;14(2):137-42. doi: 10.1097/ACI.0000000000000036.
Zotero 插件